Neurocrine Biosciences

Youtube Subscribe

Open: 115.36 Close: 115.46 Change: 0.1

Our AI found some flaws in Neurocrine Biosciences.

How much time have you spent trying to decide whether investing in Neurocrine Biosciences? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Neurocrine Biosciences are: …

Concept Map

Semantic Network

Stock Summary

Neurocrine Biosciences, Inc. discovers, develops, markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Its products include INGREZZA and DYSVAL, for the treatment of tardive dys.

Today's Summary

Neurocrine Biosciences stock looks oversold at $90 levels. Warren Buffett advises to be fearful when others are greedy, and be greedy when other people are fearful. Jefferies Financial Group increased their target price on Neurocrines.

Today's News

Neurocrine Biosciences stock, a biotech company that develops treatments for neurological and endocrine-related diseases and disorders, looks oversold at $90 levels. Warren Buffett advises to be fearful when others are greedy, and be greedy when other people are fearful. Neurocrine Biosciences to Present at Goldman Sachs 44th Annual Global Healthcare Conference 6/8/2023. Company announces appointment of Christine A. Poon to Board of Directors. Neurocrine Biosciences, Inc. reports positive top-line data from Phase 3 study of Crinecerfont 339 AFX News. FDA accepts NDA for Ingrezza Oral Granules Sprinkle Formulation. ProShare Advisors LLC lowered its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report ) last posted its quarterly earnings results on Tuesday, August 1st. Jefferies Financial Group increased their target price on Neurocrines to $123.00. Neurocrine Biosciences (NASDAQ:NBIX) is in the Health Care sector and Biotechnology industry. The stock price for Neurocrinine BioX ( NASDAQ : NBIX ) is $ 115.46 last updated September 27, 2023 at 8:00 PM UTC.

Stock Profile

"Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California."

Keywords

This document will help you to evaluate Neurocrine Biosciences without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Neurocrine Biosciences are: Neurocrine, Biosciences, stock, fearful, greedy, Inc, NASDAQNBIX, and the most common words in the summary are: neurocrine, bioscience, best, inc, stock, news, pharmaceutical, . One of the sentences in the summary was: Jefferies Financial Group increased their target price on Neurocrines.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #neurocrine #bioscience #best #inc #stock #news #pharmaceutical.

Read more →

Youtube Subscribe

---